{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:19:08Z","timestamp":1788185948186,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The efficacy and safety of maribavir, an oral benzimidazole nucleoside that inhibits viral kinase UL97, were evaluated in hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) recipients with cytomegalovirus (CMV) infection. This phase III, multicenter, open-label, single-arm, interventional study (ClinicalTrials.gov: NCT05137717; Japan Registry of Clinical Trials: jRCT2021210056) investigated oral maribavir 400\u00a0mg twice daily for 8\u00a0weeks. Japanese HSCT\/SOT recipients aged\u2009\u2265\u200916\u00a0years with symptomatic or asymptomatic CMV infection (including those resistant\/refractory to ganciclovir, valganciclovir, or foscarnet) and without central nervous system CMV tissue-invasive disease or CMV retinitis were enrolled. Primary endpoints were confirmed CMV viremia clearance at week 8 for efficacy and treatment-emergent adverse events (TEAEs) for safety. Among 61 patients enrolled across 22 sites, 41 patients (median age 56.0\u00a0years; 36\/41 [87.8%] were HSCT recipients) received\u2009\u2265\u20091 maribavir dose. At week 8, twenty-eight patients (28\/41, 68.3%) achieved confirmed CMV viremia clearance. Overall, 36 patients (36\/41, 87.8%) had\u2009\u2265\u20091 TEAE, including nausea (10\/41, 24.2%), anemia (7\/41, 17.1%), pyrexia (6\/41, 14.6%), and headache (6\/41, 14.6%). Two deaths were deemed unrelated to maribavir. In conclusion, maribavir was effective in achieving CMV viremia clearance, with an acceptable safety profile and tolerability, in Japanese HSCT or SOT recipients with CMV infection.<\/jats:p>","DOI":"10.1007\/s12185-026-04220-3","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:40:53Z","timestamp":1781250053000},"page":"429-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study"],"prefix":"10.1007","volume":"124","author":[{"given":"Yoshinobu","family":"Kanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5672-186X","authenticated-orcid":false,"given":"Kei","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"4220_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajt.12002","volume":"13","author":"JA Fishman","year":"2013","unstructured":"Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant. 2013;13:1\u20138.","journal-title":"Am J Transplant"},{"issue":"3","key":"4220_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta\u2010analysis. Rev Med Virol. 2019;29(3):e2034.","journal-title":"Rev Med Virol"},{"issue":"11","key":"4220_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","volume":"78","author":"A Meesing","year":"2018","unstructured":"Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78(11):1085\u2013103.","journal-title":"Drugs"},{"key":"4220_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ajt.12006","volume":"13","author":"CN Kotton","year":"2013","unstructured":"Kotton CN. CMV: Prevention, diagnosis and therapy. Am J Transplant. 2013;13:24\u201340.","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"4220_CR5","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","volume":"221","author":"G Haidar","year":"2020","unstructured":"Haidar G, Boeckh M, Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221(Suppl 1):S23\u201331.","journal-title":"J Infect Dis"},{"issue":"Suppl 7","key":"4220_CR6","doi-asserted-by":"publisher","first-page":"S754","DOI":"10.1093\/clinids\/12.Supplement_7.S754","volume":"12","author":"RH Rubin","year":"1990","unstructured":"Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990;12(Suppl 7):S754\u201366.","journal-title":"Rev Infect Dis"},{"issue":"20","key":"4220_CR7","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427\u201338.","journal-title":"Blood"},{"issue":"12","key":"4220_CR8","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1080\/03007995.2019.1649379","volume":"35","author":"R Ueno","year":"2019","unstructured":"Ueno R, Nishimura S, Fujimoto G, Piao Y, Takenaka K. The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan\u2014a retrospective database study. Curr Med Res Opin. 2019;35(12):2089\u201396.","journal-title":"Curr Med Res Opin"},{"issue":"9220","key":"4220_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","volume":"355","author":"VC Emery","year":"2000","unstructured":"Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355(9220):2032\u20136.","journal-title":"Lancet"},{"issue":"1","key":"4220_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13696","volume":"17","author":"K Sun","year":"2024","unstructured":"Sun K, Fournier M, Sundberg AK, Song IH. Maribavir: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13696.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"4220_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","volume":"37","author":"WL Drew","year":"2006","unstructured":"Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37(2):124\u20137.","journal-title":"J Clin Virol"},{"key":"4220_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104616","volume":"172","author":"S Chou","year":"2019","unstructured":"Chou S, Wu J, Song K, Bo T. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antivir Res. 2019;172:104616.","journal-title":"Antivir Res"},{"issue":"4","key":"4220_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690\u2013701.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4220_CR14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/cid\/ciad709","volume":"78","author":"GA Papanicolaou","year":"2024","unstructured":"Papanicolaou GA, Avery RK, Cordonnier C, Duarte RF, Haider S, Maertens J, et al. Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir. Clin Infect Dis. 2024;78(3):562\u201372.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4220_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C. Maribavir: first approval. Drugs. 2022;82(3):335\u201340.","journal-title":"Drugs"},{"key":"4220_CR16","unstructured":"Takeda Pharmaceutical Company Limited. Takeda announces approval of LIVTENCITY\u00ae (maribavir) in Japan for post-transplant cytomegalovirus (CMV) infection\/disease that is refractory to existing anti-CMV therapies. 2024. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2024\/livtencity-japan-regulatory-approval\/. Accessed April 29, 2025."},{"issue":"1","key":"4220_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87\u201391.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4220_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/infdis\/jiad293","volume":"229","author":"S Chou","year":"2024","unstructured":"Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, et al. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. J Infect Dis. 2024;229(2):413\u201321.","journal-title":"J Infect Dis"},{"key":"4220_CR19","unstructured":"Takeda Pharmaceuticals International. LIVTENCITY summary of product characteristics. European Medicines Agency. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/livtencity-epar-product-information_en.pdf. Accessed January 13, 2026."},{"key":"4220_CR20","unstructured":"Takeda Pharmaceuticals America Inc. LIVTENCITY\u00ae (maribavir) US Prescribing Information. Takeda Pharmaceutical Company Limited, Cambridge, MA. 2024. https:\/\/content.takeda.com\/?contenttype=pi&product=liv&language=eng&country=usa&documentnumber=1. Accessed January 13, 2026."},{"issue":"6","key":"4220_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s10928-024-09939-2","volume":"51","author":"IH Song","year":"2024","unstructured":"Song IH, Chen G, Hayes S, Farrell C, Jomphe C, Gosselin NH, et al. Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with cytomegalovirus infection. J Pharmacokinet Pharmacodyn. 2024;51(6):887\u2013904.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"4220_CR22","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/psp4.70054","volume":"14","author":"K Sun","year":"2025","unstructured":"Sun K, Jomphe C, Gosselin NH, Pheng L, Durairaj C, Hang Y, et al. Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with first episode or refractory cytomegalovirus. CPT Pharmacomet Syst Pharmacol. 2025;14(8):1346\u201358.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"4220_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood.V97.4.867","volume":"97","author":"WG Nichols","year":"2001","unstructured":"Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97(4):867\u201374.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04220-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:47Z","timestamp":1788184607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04220-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4220"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04220-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KKa, KKu, and MK are employees of Takeda Pharmaceutical Company Limited, Osaka, Japan and hold stock and\/or stock options from Takeda. YK reports relationships with Mitsubishi Tanabe Pharma Corporation, Viatris, and Clinigen, and lecture fees from MSD. YK is an Associate Editor of the International Journal of Hematology. KT, TT, and KO declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}